Insider

Altria reports third-quarter results and expands share repurchase program

On October 29, 2026, Altria Group, Inc. reported financial results for the quarter ended September 30, 2026. Revenue was $6.1 billion, and diluted earnings per share (EPS) were $1.51. The board of directors approved a $1 billion increase to the existing share repurchase program.

Verified against 4 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
a black and white photo of workers in a factory
Photo by East Riding Archives on Unsplash
$6.1 billion
Quarterly revenue
$1.51
Diluted EPS
5.9 million
Shares repurchased

Key points

  • In the third quarter of 2026, Altria reported $6.1 billion in revenue.
  • In the oral tobacco products segment, operating income before general corporate expenses and amortization of intangibles (OCI) decreased 5.4% due to lower shipment volumes, higher costs, and increased promotional investments.

Financial results and share repurchases

In the third quarter of 2026, Altria reported $6.1 billion in revenue. Diluted earnings per share (EPS) grew 7.1% year-over-year. The company repurchased 5.9 million shares for a total of $400 million during the quarter.

The board of directors approved the $1 billion expansion of the share repurchase program on October 28, 2026, as part of its capital return strategy for shareholders.

Revenue by quarter, $B

6Q4 '24*48.2%5.3Q1 '2534%6.1Q2 '2552.9%6.1Q3 '2553.2%5.8Q4 '25*28.2%5.4Q1 '2654.5%6.1Q2 '2651.3%6.1Q3 '2654%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector context: 18 covered companies in Consumer Staples reported a median revenue change of +5.4% YoY in their latest filings.

Operational risks and regulatory changes

In the oral tobacco products segment, operating income before general corporate expenses and amortization of intangibles (OCI) decreased 5.4% due to lower shipment volumes, higher costs, and increased promotional investments. New California legislation banning the manufacture and import of single-use e-vapor products starting in January 2027, and their retail sale from January 2028, adds further uncertainty.

The company is also involved in litigation regarding delays in issuing marketing orders for new tobacco products (PMTAs), creating uncertainty about future regulatory pathways for these products.

What to watch

Investors should monitor future company reports on shares outstanding to gauge the actual execution of the repurchase program. Tracking OCI in the oral tobacco products segment is also important to see if the company can stabilize profitability there.

Original sources

  1. 8-K EX-99.1 filing, October 29, 2026October 29, 2026SHA-256 of our archived copy 269b4acfebce…
  2. 8-K filing, October 29, 2026October 29, 2026SHA-256 of our archived copy 04169228118a…
  3. 10-Q risk factors compared with the 10-Q filing, July 30, 2026October 29, 2026SHA-256 of our archived copy fa2e94a70d8b…
  4. financial data (XBRL)October 29, 2026SHA-256 of our archived copy df6e275fb3c3…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards